A double-blind, placebo-controlled study of paroxetine in depressed outpatients.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Journal of Clinical Psychiatry

• Publication date

  1992-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  PMID 1531818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients.

  1992cited by this paper
• Meta‐analysis of early phase I1 studies with paroxetine in hospitalized depressed patients

  1989cited by this paper
• A placebo‐controlled, double‐blind, clinical trial of paroxetine in depressed outpatients

  1989cited by this paper
• Pharmacological effects of paroxetine after repeated administration to animals

  1989cited by this paper
• An overview of the animal pharmacology of paroxetine

  1989cited by this paper
• A double‐blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients

  1989cited by this paper

• Meta-analysis: Second generation antidepressants and headache.

  2018cites this paper
• Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis

  2017cites this paper
• Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.

  2015cites this paper
• Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram

  2015cites this paper
• The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-Analysis of Change on the Hamilton Rating Scales

  2014cites this paper
• Pharmacological management of unipolar depression

  2013cites this paper
• Randomized, Placebo-Controlled Trials of Antidepressants for Acute Major Depression: Thirty-Year Meta-Analytic Review

  2012cites this paper
• Эффективность паксила при лечении депрессий у мужчин пожилого возраста

  2012cites this paper
• Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials.

  2011cites this paper
• Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials

  2009cites this paper
• Clinical practice recommendations for depression

  2009cites this paper
• new drug applications pharmaceutical industry: review of studies in reporting from studies sponsored by Evidence b(i)ased medicine—selective

  2008cites this paper
• Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration

  2008cites this paper
• Common adverse events associated with an SSRI: meta‐analysis of early paroxetine data

  2008cites this paper
• Not all placebos are the same: a debate on the ethics of placebo use in clinical trials versus clinical practice

  2007cites this paper
• Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis.

  2007cites this paper
• Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials

  2007cites this paper
• Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports

  2007influential citation
• Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.

  2006cites this paper
• Is there a delay in the antidepressant effect? A meta-analysis.

  2005cites this paper
• [Rexetin in the therapy of depressive states].

  2005cites this paper
• Australian and New Zealand Clinical Practice Guidelines for the Treatment of Depression

  2004cites this paper
• Australian and New Zealand clinical practice guidelines for the treatment of depression.

  2004cites this paper
• Die klinische Besserungsrate unter Antidepressivatherapie

  2004cites this paper
• Does elimination of placebo responders in a placebo run‐in increase the treatment effect in randomized clinical trials? A meta‐analytic evaluation

  2004cites this paper
• Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials

  2003cites this paper
• Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

  2003cites this paper
• Treating depression: the beyondblue guidelines for treating depression in primary care. "Not so much what you do but that you keep doing it".

  2002cites this paper
• Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression

  2000cites this paper
• Latency to paroxetine‐induced anxiolysis in the rat is reduced by co‐administration of the 5‐HT1A receptor antagonist WAY100635

  2000cites this paper
• Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders.

  1999cites this paper
• Validated chiral high-performance liquid chromatographic method for the determination of trans-(-)-paroxetine and its enantiomer in bulk and pharmaceutical formulations.

  1998cites this paper
• Paroxetine: a Review of Clinical Experience

  1998cites this paper
• Treatment of depression--newer pharmacotherapies.

  1998cites this paper
• Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

  1998cites this paper
• [Choice of therapeutic tactics in treatment of endogenous depression by means of statusmetric expert system].

  1997cites this paper
• A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.

  1997cites this paper
• Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients.

  1996cites this paper
• Measures of Global Functioning

  1995cites this paper
• Anxiolytic-like effect of paroxetine in a rat social interaction test.

  1994cites this paper
• The Clinical Pharmacology and Use of Paroxetine, a New Selective Serotonin Reuptake Inhibitor

  1994cites this paper
• Efficacy, safety, and indications for tricyclic and newer antidepressants

  1994cites this paper
• Criteria for use of paroxetine hydrochloride in adult inpatients and outpatients. American Society of Hospital Pharmacists.

  1994cites this paper
• The continuing unethical use of placebo controls.

  1994cites this paper
• Nicht-trizyklische Antidepressiva

  1993cites this paper
• Clinical management of the depressed geriatric patient: current therapeutic options.

  1993cites this paper
• Paroxetine: An Overview of the Efficacy and Safety of a New Selective Serotonin Reuptake Inhibitor in the Treatment of Depression

  1993cites this paper
• Paroxetine: A Selective Serotonin Reuptake Inhibiting Antidepressant

  1993cites this paper
• A study comparing paroxetine placebo and imipramine in depressed patients.

  1993cites this paper
• Paroxetine in the treatment of depression: a comparison with imipramine and placebo.

  1992cites this paper